The Effect of Spironolactone Use on Heart Failure Mortality: A Population-Based Study

Journal of Cardiac Failure

Volumn 13, Issue 3, 2007, Pages 165-169

  Ouzounian, Maral ^a   Hassan, Ansar ^a   Cox, Jafna L ^a   Johnstone, David E ^a   Howlett, Jonathan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Aldosterone antagonism; Congestive heart failure; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGED; COHORT STUDIES; COMORBIDITY; CREATININE; DIABETES MELLITUS; DIURETICS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; NOVA SCOTIA; PATIENT DISCHARGE; SEX DISTRIBUTION; SPIRONOLACTONE; STROKE VOLUME; SURVIVAL ANALYSIS;

EID: 34247173498     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.11.016     Document Type: Article

References (13)

1. O'Connell J.B., and Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 13 (1993) S107-S112
2. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 38 (2001) 2101-2113
3. Liu P., Arnold J.M., Belenkie I., et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 19 (2003) 347-356
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
5. Cox J.L., Ramer S.A., Lee D.S., Humphries K., Pilote L., Svenson L., Tu J.V., and on behalf of the Canadian Cardiovascular Outcomes Research Team Investigators. Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Can J Cardiol 21 (2005) 337-343
6. Canadian Cardiovascular Outcomes Research Team Investigators. Burden of cardiovascular disease in Canada. Can J Cardiol 19 (2003) 997-1004
7. Cox J.L., and ICONS Investigators. Optimizing disease management at a health care system level: the rationale and methods of the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Can J Cardiol 15 (1999) 787-796
8. Pitt B., and Perez A. Spironolactone in patients with heart failure. N Engl J Med 342 (2000) 133-134
9. Berry C., and McMurray J.J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85 (2001) E8
10. Schepkens H., Vanholder R., Billiouw J.M., and Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 (2001) 438-441
11. Svensson M., Gustafsson F., Galatius S., Hildebrandt P.R., and Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 327 (2003) 1141-1142
12. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
13. McAlister F.A., Stewart S., Ferrua S., and McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 (2004) 810-819